Full Archive
Risk factors influencing postoperative pleural empyema in patients with pleural mesothelioma: a retrospective single-centre analysis
European Journal of Cardiothoracic Surgery 2024 March 29 [Link] Peter Henschke, Laura Chiara Guglielmetti, Sven Hillinger, Gian-Marco Monsch, Didier Schneiter, Isabelle Opitz, Olivia Lauk Abstract Objectives: Postoperative empyema is a severe, potentially lethal complication also present, but poorly studied in patients undergoing surgery for pleural mesothelioma. We aimed to analyse which perioperative characteristics might be…
Read MoreDiffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features
Clinical Cancer Research 2024 April 7 [Link] Soo-Ryum Yang, Gowtham Jayakumaran, Jamal Benhamida, Christopher A Febres Aldana, Rachel Fanaroff, Jason Chang, Erika Gedvilaite, Liliana B Villafania, Jennifer L Sauter, Michael Offin, Marjorie G Zauderer, Marc Ladanyi Abstract Purpose: Diffuse pleural mesotheliomas (DPMs) with genomic near-haploidization (GNH) represent a novel subtype first recognized by the TCGA…
Read MoreCirculating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma
Thoracic Cancer 2024 April 16 [Link] Juuso Paajanen, Ahmed Sadek, William G Richards, Yue Xie, Emanuele Mazzola, Kristina Sidopoulos, John Kuckelman, Ritu R Gill, Raphael Bueno Abstract Background: Tumor recurrence remains the main barrier to survival after surgery for pleural mesothelioma (PM). Soluble mesothelin-related protein (SMRP) and cancer antigen 125 (CA-125) are established blood-based biomarkers…
Read MoreDevelopment of Patient and Caregiver Conceptual Models Investigating the Health-Related Quality of Life Impacts of Malignant Pleural Mesothelioma
The Patient 2024 April 15 [Link] Adam E J Gibson, Waqas Ahmed, Louise Longworth, Bryan Bennett, Melinda Daumont, Liz Darlison Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and usually fatal malignancy frequently linked to occupational asbestos exposures and associated with poor prognosis and considerable humanistic burden. The study aimed to develop conceptual models…
Read MoreEmerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma
Cancers 2024 March 22 [Link] Karen M Yun, Lyudmila Bazhenova Abstract Malignant pleural mesothelioma (MPM) is a heterogeneous cancer composed of distinct molecular and pathologic subtypes. Unfortunately, MPM is aggressive, and current therapies for advanced, unresectable disease remain limited to cytotoxic chemotherapy and immunotherapy. Our understanding of the genomic landscape of MPM is steadily growing,…
Read MoreHigh mobility group box 1 mediates inflammatory responses in malignant peritoneal mesothelioma
International Immunopharmacology 2024 April 12 [Link] Lianfen Wang, Xuesong Wang, Ningning Sun, Weili Liu Abstract Background: Serum high mobility group box 1 (HMGB1) serves as a diagnostic biomarker for malignant peritoneal mesothelioma (MPM) patients, yet its diagnostic significance within MPM tumor tissues remains uncertain. This study aims to elucidate the roles of HMGB1 in MPM.…
Read MoreYAP/TAZ-TEAD signalling axis: A new therapeutic target in malignant pleural mesothelioma
Journal of Cellular and Molecular Medicine 2024 April [Link] Kostas A Papavassiliou, Amalia A Sofianidi, Athanasios G Papavassiliou Abstract The Hippo signalling pathway, a highly conserved signalling cassette, regulates organ size by controlling cell growth, apoptosis and stem cell self-renewal. The tumourigenic potential of this pathway is largely attributed to the activity of YAP/TAZ, which…
Read MoreDiagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis
Pathology, Research, and Practice 2024 March 30 [Link] Rafael Parra-Medina, Juan Pablo Castañeda-González, Viviana Chaves-Cabezas, Juan Pablo Alzate, Juan José Chaves Abstract Background: Malignant pleural mesothelioma (MPM) poses diagnostic challenges due to its resemblance to benign pleural pathologies and different histological subtypes. Several immunohistochemistry markers have been employed to aid in accurate diagnosis. Methods: The…
Read MoreLow Exposures to Amphibole or Serpentine Asbestos in Germline Bap1-mutant Mice Induce Mesothelioma Characterized by an Immunosuppressive Tumor Microenvironment
Cancer Research Communications 2024 April 8 [Link] Yuwaraj Kadariya, Eleonora Sementino, Maggie Ruan, Mitchell Cheung, Parham Hadikhani, Hatice U Osmanbeyoglu, Andres J Klein-Szanto, Kathy Cai, Joseph R Testa Abstract Asbestos and BAP1 germline mutations are risk factors for malignant mesothelioma (MM). While it is well accepted that amphibole asbestos is carcinogenic, the role of serpentine…
Read MoreThe role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies-experience from a tertiary care center in Germany
Langenbeck’s Archives of Surgery 2024 April 8 [Link] Mikko Reese, Ann-Kathrin Eichelmann, Tobias M Nowacki , Andreas Pascher, Judith C Sporn Abstract Purpose: Peritoneal surface malignancies (PSM) are commonly known to have a dismal prognosis. Over the past decades, novel techniques such as cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and pressurized intraperitoneal aerosol chemotherapy…
Read More